Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate

Cancer

Volumn 83, Issue 10, 1998, Pages 2172-2180

  D'Amico, Anthony V ^a   Desjardin, April ^b   Chen, Ming Hui ^b   Paik, Steve ^a   Schultz, Delray ^c   Renshaw, Andrew A ^d   Loughlin, Kevin R ^d   Richie, Jerome P ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Worcester Polytechnic Institute   (United States)

^c University of Millersville   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Prostate carcinoma; Prostate carcinoma volume; Prostate specific antigen; Radiation therapy; Radical prostatectomy; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0032533584     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981115)83:10<2172::AID-CNCR16>3.0.CO;2-K     Document Type: Article

References (35)

1. Smith D, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994;152:1732-5.
2. Culp OS. Radical perineal prostatectomy: its past, present, and possible future. J Urol 1968;98:625-25.
3. Jewett HJ, Eggleston JC, Yawn DH. Radical prostatectomy in the management of carcinoma of the prostate: probable causes of some therapeutic failures. J Urol 1972;107:1034-40.
4. Benson RC Jr., Tomera KM, Zincke H, Fleming TR, Utz DC. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J Urol 1984;131:1103-7.
5. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 1989;142:1262-5.
6. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6.
7. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-7.
8. Beahrs OH, Henson DE, Hutter RVP. American Joint Committee on Cancer manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott, 1992.
9. D'Amico AV, Whittington R, Malkowicz SB, Tomaszewski JE, Schultz D, Wein A. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997;158: 1422-6.
10. D'Amico AV, Chang H, Holoupka E, Renshaw A, Desjardin A, Chen M, et al. Calculated prostate cancer volume: the optimal predictor of the actual prostate cancer volume. Urology 1997;49:385-91.
11. Gleason DF and the Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology. Philadelphia: Lea & Febiger, 1977:171-87.
12. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Pironen T, Abrahamsson P, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
13. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187.
14. Cox JD. PSA following irradiation: conclusions of ASTRO Consensus Conference. Int J Radiat Oncol Biol Phys 1996; 36S:113-6.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-500.
16. Akaike H. Factor analysis and AIC. Psychometrika 1987;52: 317-32.
17. Schwartz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
18. Efron R, Tibsherani R. Introduction to the bootstrap. New York: Chapman and Hall, 1993.
19. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32:293-306.
20. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer 1997;79:337-44.
21. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external beam radiotherapy alone: serum prostate specific antigen driven outcome analysis. J Clin Oncol 1995;13:464-9.
22. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wie HS. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
23. AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
24. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
25. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-8.
26. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-3.
27. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate. The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-3.
28. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. PSA failure despite pathologically organ confined and margin negative disease: the basis for an adjuvant therapy trial. J Clin Oncol 1997;15:1465-9.
29. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-1.
30. Carter HB, Pearson JL, Metter J, Brant LJ, Chan DW, Andres R. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267:2215-20.
31. Partin AW, Kattan MW, Subong ENP, Walsh P, Wojno KJ, Oesterling JE, et al. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277;1445-51.
32. Roach M, Marquez C, Yuo H-S, Narayan P, Coleman L, Nseyo UO. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1993;28:33-7.
33. D'Amico AV, Propert K. Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 1996;35:273-9.
34. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ. Evaluation of the prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-54.
35. Bolla M, Gonsalez D, Warde P, Dubois JB, Mirimanoff R, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.